Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1All patients in the study will be treated with ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
2Continued Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		[10] D01370 ,
D02802 ,
D02994 ,
D03846 ,
D05218 (Name: Ocrelizumab),
D06886 ,
D09314 ,
D10001 ,
D10172 ,
D11215 		[7] CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		-[1] 13
4OCRELIZUMAB[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[3] 13, 46, 49
5Ocrelizumab (CinnaGen, Iran)[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
6Ocrelizumab (Roche, Switzerland)[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
7Ocrelizumab / rhuMAb 2H7[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 46
8Ocrelizumab 300 mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
9Ocrelizumab 300mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
10Ocrelizumab 300mg /10ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
11Ocrelizumab 300mg/10 ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
12Ocrelizumab 300mg/10ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
13Ocrelizumab 500mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 46
14Ocrelizumab 600 mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
15Ocrelizumab at home[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
16Ocrelizumab Dose 1[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
17Ocrelizumab Dose 2 and Dose 3[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
18Ocrelizumab IV[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
19Ocrelizumab SC[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
20Ocrelizumabu 200mg----[1] 46
21Ocrelizumabu 50mg----[1] 46
22Perfusion of treatment Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
23Short-course Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13